Arthneeti
All Q4 FY26 results →
IC

IOL Chemicals & Pharmaceuticals Ltd

Q4 FY26Pharmaceuticals & Biotechnology

IOL Chemicals & Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹170
Market cap₹4.8K Cr
P/E32.8
Updated23 Aug 2026
Read4 min read

The short version

The company expects mid- to high-teen percentage revenue growth in FY 2027 and beyond. Company expects mid-teen to high-teen revenue growth for FY 2027 and over the medium term.

From IOL Chemicals & Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company expects mid- to high-teen percentage revenue growth in FY 2027 and beyond.
  • Targeted top-line growth is around 15% annually on existing capacity.
  • Maximum revenue potential from existing capacity is estimated at INR 3,200 to 3,300 crores.
  • Capacity utilization for paracetamol expected to rise from 55% to 70-75% in FY 2027 and reach full capacity in FY 2028.
  • Ibuprofen business growth anticipated at 3%-4% annually with further export market expansion.
  • Non-ibuprofen exports expected to grow, with a target to reach about 25% export share in FY 2027.

2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what IOL Chemicals & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company has acquired 100 acres of land near Bhatinda Highway for a new mega project.
  • Regulatory approvals are underway; environmental clearances are obtained.
  • The new project is expected to commence within 4 to 8 quarters (1 to 2 years).
  • The total capital outlay for this greenfield project is estimated between INR 1,200 to INR 1,400 crores.
  • Annual capex at the new site is planned around INR 200 to 250 crores, to be funded through internal accruals.
  • The overall capex will be phased and is expected to be completed over the next 4 to 5 years.

2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what IOL Chemicals & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided does not explicitly mention the current or expected order book or pending orders for IOL Chemicals and Pharmaceuticals Limited. However, relevant points related to company outlook and growth include: - The company is targeting around INR 2,700 crores in revenue for FY 2027, with mid-teen revenue growth expected annually. - Capacity utilization is high across key products (around 85%-95% for most products; paracetamol capacity utilization expected to rise from 55% to 75%). - Export share, especially for non-ibuprofen products, is expected to increase to around 25% in FY 2027.

2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on order book

Pro opens every point from 15K+ earnings calls

IOL Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹619 Cr, net profit ₹53 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What IOL Chemicals's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pha. (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn Ltd (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

IOL Chemicals & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were IOL Chemicals & Pharmaceuticals Ltd Q4 FY26 results?

The company expects mid- to high-teen percentage revenue growth in FY 2027 and beyond. Company expects mid-teen to high-teen revenue growth for FY 2027 and over the medium term.

What is IOL Chemicals & Pharmaceuticals Ltd share price analysis?

IOL Chemicals & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 32.8 with a market cap of ₹4,797 Cr. Investors should review the full earnings analysis for detailed insights.

Is IOL Chemicals & Pharmaceuticals Ltd planning capital expenditure?

The company has acquired 100 acres of land near Bhatinda Highway for a new mega project.

Keep IOL Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.